Metabolic research has become the centre of gravity for the entire peptide field. A decade ago the compounds most requested by research suppliers were tissue-repair and growth-hormone-releasing peptides; today the incretin class dominates, and the wider category of weight-management research peptides now includes molecules that act on appetite, energy expenditure, fat metabolism and mitochondrial signalling through several distinct mechanisms. The shift has been driven by clinical results that were, by the standards of obesity pharmacology, without precedent, and by a research community eager to understand how those results were achieved.
This article ranks the ten weight-management research peptides that are most in demand among researchers in 2026, based on the volume of interest across the research-supply market, the depth of the clinical and preclinical literature, and the pace of ongoing investigation. The ranking is not a claim about which compound is “best”; several are approved medicines in other forms, several are investigational, and several have never been studied in humans at all. It is a map of where attention is currently concentrated and why.
One point governs everything that follows. Every compound below, when sold by a research-peptide supplier, is a laboratory reagent and not a medicine. Retatrutide in particular is an investigational molecule with no approval from Health Canada, the FDA or any regulator; researchers seeking Retatrutide canada supply are buying it for laboratory study, and a supplier such as NOX Peptides Canada labels and sells it accordingly. This article describes trial findings factually, gives no dosing or administration guidance, and is not medical advice.
1. Retatrutide
Retatrutide sits at the top of the list because it has become, in a very short time, the compound that researchers in metabolic science most want to work with. Developed by Eli Lilly, it is a single peptide engineered to act as an agonist at three receptors simultaneously: GLP-1, GIP and glucagon. The first two targets are shared with Tirzepatide; the addition of glucagon receptor activity is what distinguishes Retatrutide and, in principle, what allows it to increase energy expenditure and hepatic fat metabolism in addition to suppressing appetite.
The clinical data that drove the interest came from a phase 2 trial in adults with obesity, which reported substantial mean weight reduction over the study period, with the higher-dose arms producing figures that exceeded what earlier single- and dual-agonist trials had shown at comparable durations. Those results are from a mid-sized trial, however, and the compound is now in the phase 3 TRIUMPH programme, which is evaluating it in larger populations and over longer periods. Until those trials report and a regulator reviews them, Retatrutide has no approved use anywhere, and comparisons with approved drugs across different trials should be treated with caution.
For researchers, the molecule presents specific sourcing challenges. It is large, heavily modified with a fatty diacid side chain, expensive to synthesise correctly, and in high demand, which makes it a prime candidate for substitution and underfilling in the unregulated market. Independent, batch-specific testing by HPLC and mass spectrometry is essential. NOX Peptides Canada stocks Retatrutide in a 30 mg research vial with a third-party COA published per lot, stored cold and shipped within Canada, which addresses the main risks in a single listing.
2. Tirzepatide
Tirzepatide is the dual GLP-1 and GIP receptor agonist that preceded Retatrutide in Lilly’s pipeline and that is now approved in several jurisdictions, including Canada, as a prescription medicine for type 2 diabetes and for chronic weight management. In research settings it is studied both as a compound in its own right and as the natural comparator for triple agonists: the question of what the glucagon receptor adds is, in effect, the question of how Retatrutide differs from Tirzepatide.
The clinical literature on Tirzepatide is extensive, with the SURMOUNT and SURPASS programmes covering obesity and diabetes populations respectively. Its mechanism, the combined activation of two incretin receptors, produced weight reductions in trials that exceeded those seen with GLP-1 monotherapy. In the research market it is available as a lyophilised reagent from the same suppliers that stock Retatrutide, and it carries the same considerations: identity confirmation by mass spectrometry, batch-specific purity data, and correct handling of a lipidated peptide. Research-grade Tirzepatide is not the approved pharmaceutical product and should not be confused with it.
3. Semaglutide
Semaglutide is the GLP-1 receptor agonist that made the incretin class a household name. Approved as a medicine for type 2 diabetes and for weight management under different brand names, it has the longest and deepest clinical record of any compound on this list, spanning the STEP trials in obesity, the SUSTAIN trials in diabetes and cardiovascular outcome studies. Its mechanism is single-receptor: it activates GLP-1 receptors to slow gastric emptying, increase satiety and enhance glucose-dependent insulin secretion.
In the research market, Semaglutide is popular for the same reason Tirzepatide is: it is the established baseline against which newer multi-agonists are measured. It is also the compound for which counterfeit and mislabelled product has been most widely reported, a consequence of enormous demand meeting an unregulated supply chain. Researchers ordering Semaglutide as a reagent should apply exactly the same testing standards they would to Retatrutide. A supplier that documents one properly will usually document the other.
4. Cagrilintide
Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk, and it represents a different mechanism from the incretin agonists. Amylin is a hormone co-secreted with insulin that slows gastric emptying and promotes satiety through pathways distinct from GLP-1. Cagrilintide has been studied both as a monotherapy and, more prominently, in fixed combination with Semaglutide, an investigational pairing that has reported substantial weight reduction in clinical trials.
Research interest in Cagrilintide has grown as the field has moved toward combining mechanisms rather than escalating a single one. As a reagent it appears in the research market less frequently than the incretins and is correspondingly harder to source with reliable documentation. It has no regulatory approval as a standalone product. For researchers, it is the compound to study when the question is how amylin signalling interacts with incretin signalling, a question that is central to the next generation of metabolic therapeutics.
5. AOD-9604
AOD-9604 is a modified fragment of human growth hormone, corresponding to the C-terminal region of the molecule that was hypothesised to carry its lipolytic activity without its effects on growth or insulin sensitivity. It was developed in Australia in the early 2000s and progressed through clinical trials as a potential anti-obesity agent before development was discontinued when the trials did not meet their efficacy endpoints.
Its continued popularity in the research market reflects the durability of the underlying hypothesis rather than any clinical success. The compound remains of interest for studies of fat metabolism in cell and animal models, and it has been the subject of some later work on cartilage and joint tissue. Researchers should be aware that its human weight-loss data are negative and that claims to the contrary in marketing material are not supported. It is a research reagent with a well-defined history and an open scientific question, not a proven agent.
6. Tesamorelin
Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone that stimulates the pituitary to release growth hormone in a pulsatile pattern. It is unusual on this list in having a specific regulatory approval, in the United States, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. That indication rests on trials that measured visceral adipose tissue directly by imaging, and it makes Tesamorelin one of the few peptides with a fat-related approved use, albeit a narrow one.
In research, Tesamorelin is studied for its effects on visceral fat, on hepatic fat in the context of fatty liver disease, and on the broader physiology of growth hormone secretagogues. It is not approved for general weight management, and its mechanism, elevating growth hormone and downstream IGF-1, carries physiological trade-offs including effects on glucose metabolism that researchers must account for. Research-grade Tesamorelin is a distinct product from the approved pharmaceutical and should be documented as such.
7. MOTS-c
MOTS-c is a mitochondrial-derived peptide, a short sequence encoded in the mitochondrial genome rather than the nuclear genome, discovered in the mid-2010s. It has been studied for its role as a signalling molecule regulating metabolic homeostasis, particularly in skeletal muscle, where it appears to influence insulin sensitivity and fatty-acid metabolism through AMPK-related pathways. Rodent studies have reported effects on diet-induced obesity and exercise capacity.
MOTS-c is of interest to researchers because it represents an entirely different axis from the gut-hormone agonists that dominate the list. It has been evaluated in early human trials, but there is no approved use and the clinical literature is thin compared with the incretins. It is a compound for mechanistic and preclinical study, and any research-supply listing that implies established human effects is overstating the evidence.
8. CJC-1295 and Ipamorelin
These two growth hormone secretagogues are listed together because they are almost always requested together in the research market. CJC-1295 is a GHRH analogue, available with or without a drug affinity complex modification that extends its half-life; Ipamorelin is a selective ghrelin receptor agonist that stimulates growth hormone release with comparatively little effect on cortisol or prolactin. Combined, they act on two distinct pathways to increase pulsatile growth hormone secretion.
Their popularity in weight-management research stems from the lipolytic effects of growth hormone and from a long-standing interest in whether stimulating endogenous release avoids some of the drawbacks of exogenous growth hormone. The human evidence for weight management is limited and neither compound has regulatory approval for any indication. Elevated growth hormone and IGF-1 signalling carries known trade-offs, including effects on insulin sensitivity, that researchers must consider. As reagents they are widely available and, being smaller and simpler than the lipidated incretins, are generally easier to source with reliable purity data.
9. 5-Amino-1MQ
5-Amino-1MQ is technically a small molecule rather than a peptide, but it has become part of the research-peptide market’s weight-management category and is worth including for that reason. It is an inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that is upregulated in adipose tissue in obesity and that influences cellular NAD+ levels and energy metabolism. Inhibiting NNMT in rodent models has been reported to reduce fat mass and improve metabolic markers.
The compound is of interest as a representative of the NAD+ and cellular-energy axis, which connects to the broader popularity of NAD+ itself in the research and wellness markets. Its human data are minimal, it has no regulatory approval, and its inclusion here reflects research interest rather than any established effect. Buyers should note that as a small molecule it is characterised by different analytical methods from peptides, and a supplier’s COA should reflect that.
10. Survodutide and the Emerging Dual Agonists
The final entry is less a single compound than a category. Survodutide, developed by Boehringer Ingelheim and Zealand Pharma, is a dual GLP-1 and glucagon receptor agonist that has reported substantial weight reduction in phase 2 trials and is in phase 3 development for obesity and for metabolic liver disease. Other dual and triple agonists with varying receptor profiles are in earlier stages of development at several companies.
These compounds are on the list because they define where the field is going. The question of which combination of GLP-1, GIP, glucagon and amylin activity produces the best balance of efficacy and tolerability is the central open question in metabolic pharmacology, and each new molecule is a data point. In the research market they are available inconsistently and often without adequate documentation, since demand has outpaced the supply of properly synthesised material. Researchers seeking them should apply the most stringent testing standards and should expect that a domestic supplier with published COAs, such as NOX Peptides Canada, will add compounds to its catalogue only when it can document them properly.
Frequently Asked Questions
Why is Retatrutide ranked above approved medicines like Semaglutide and Tirzepatide?
The ranking reflects research demand, not clinical status. Retatrutide is investigational and unapproved, but its phase 2 results and the ongoing TRIUMPH phase 3 programme have made it the compound researchers most want to study in 2026. Semaglutide and Tirzepatide have far deeper clinical records and are approved medicines in other forms; as research reagents they are in demand mainly as comparators.
Are research-grade versions of these peptides the same as the pharmaceutical products?
No. Research-grade peptides are synthesised and sold as laboratory reagents. They are not manufactured under pharmaceutical GMP standards, are not sterile-filled as injectable medicines, and carry no regulatory approval. A vial of research-grade Semaglutide is a chemical for laboratory use, not the prescription drug of the same name.
What testing should a researcher expect from a supplier?
At minimum, a batch-specific certificate of analysis from an independent laboratory showing identity by mass spectrometry and purity by HPLC, with the chromatogram and spectrum visible. Endotoxin and net peptide content results are marks of a more thorough supplier. NOX Peptides Canada publishes such documentation for each lot it sells, and that standard is the appropriate benchmark for any listing.
Does the popularity of a compound indicate that it is safe?
Not at all. Popularity in the research market tracks scientific interest and, in some cases, hype, not safety data. Several compounds on this list have negative or minimal human data. All are sold for laboratory research only and none should be treated as safe for human use on the basis of their research popularity.
Final Thoughts
The weight-management research field in 2026 is defined by a single trend: the movement from one mechanism to several. Semaglutide showed what a GLP-1 agonist could do; Tirzepatide added GIP; Retatrutide added glucagon; Cagrilintide brought amylin; and the next generation is exploring every combination among them. Around that central story sit older and more speculative compounds, from growth hormone secretagogues to mitochondrial peptides to NNMT inhibitors, each representing a different hypothesis about how energy balance can be shifted.
For researchers, the practical implication is that the compounds most worth studying are also the compounds most at risk of substitution and mislabelling in an unregulated market. Sourcing discipline matters more now than it ever has. Canadian researchers looking for Retatrutide 30 mg with batch-specific third-party testing, cold storage and domestic shipping will find NOX Peptides Canada built to those specifications. Whatever the compound and whatever the supplier, the same rule applies: these are investigational research reagents, unapproved by Health Canada or the FDA for human use, and nothing in a popularity ranking, or in this article, is medical advice.
